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Myocyte Enhancer Factor 2 and Class II Histone
Deacetylases Control a Gender-Specific Pathway of
Cardioprotection Mediated by the Estrogen Receptor
Eva van Rooij, Jens Fielitz, Lillian B. Sutherland, Victor L. Thijssen, Harry J. Crijns,
Michael J. Dimaio, John Shelton, Leon J. De Windt, Joseph A. Hill, Eric N. Olson
Rationale: Gender differences in cardiovascular disease have long been recognized and attributed to beneficial
cardiovascular actions of estrogen. Class II histone deacetylases (HDACs) act as key modulators of heart disease
by repressing the activity of the myocyte enhancer factor (MEF)2 transcription factor, which promotes
pathological cardiac remodeling in response to stress. Although it is proposed that HDACs additionally influence
nuclear receptor signaling, the effect of class II HDACs on gender differences in cardiovascular disease remains
unstudied.
Objective: We aimed to examine the effect of class II HDACs on post–myocardial infarction remodeling in male and
female mice.
Methods and Results: Here we show that the absence of HDAC5 or -9 in female mice protects against maladaptive
remodeling following myocardial infarction, during which there is an upregulation of estrogen-responsive genes
in the heart. This genetic reprogramming coincides with a pronounced increase in expression of the estrogen
receptor (ER) gene, which we show to be a direct MEF2 target gene. ER also directly interacts with class II
HDACs. Cardioprotection resulting from the absence of HDAC5 or -9 in female mice can be attributed, at least
in part, to enhanced neoangiogenesis in the infarcted region via upregulation of the ER target gene vascular
endothelial growth factor-a.
Conclusions: Our results reveal a novel gender-specific pathway of cardioprotection mediated by ER and its
regulation by MEF2 and class II HDACs. (Circ Res. 2010;106:155-165.)
Key Words: estrogen receptor  cardiac remodeling  myocardial infarction  class II HDACs
Heart failure secondary to myocardial infarction (MI) andischemic cardiomyopathy is the primary cause of car-
diovascular mortality. Cardiac remodeling following MI in-
duces expansion and alterations in the infarcted and nonin-
farcted regions of the heart and increases internal load, which
promotes further stress, dilation, and hypertrophy of the
noninfarcted area.1 Although neoangiogenesis within the
infarcted tissue is also an integral component of the remod-
eling process, the microvascular network that develops fol-
lowing MI is generally unable to support the increased
demands of the hypertrophied myocardium, resulting in
progressive loss of viable tissue, infarct extension and fibrous
replacement.2 For reasons that remain incompletely under-
stood, premenopausal women appear to be partially protected
against remodeling of the infarct area and remote myocardi-
um during the course of ischemic cardiomyopathy because of
the presence of estrogen.3
Estrogen receptors (ERs) are ligand-dependent transcrip-
tion factors that mediate cardioprotective processes such as
vasodilation and angiogenesis, which limit myocardial re-
modeling after infarction and attenuate cardiac hypertrophy.4
After estrogen binding, the ER undergoes a conformational
change, which allows the receptor to dissociate from chaper-
one proteins and translocate to the nucleus where it binds
DNA and activates estrogen-responsive genes.5 Like other
nuclear hormone receptors, the activity of the ER is also
modulated by association with histone acetyltransferases and
histone deacetylases (HDACs).6
There are 2 general classes of HDACs that have been
shown to have profound influences on the response of the
heart to stress.7 Class I HDACs (HDACs 1, 2, and 3) are
relatively simple in structure, containing only a catalytic
domain, which efficiently deacetylates histones. HDACs 1
and 2 function redundantly to control myocardial growth.8,9
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HDAC2 also functions as a positive regulator of myocyte
hypertrophy in response to stress and appears to be a key
target for HDAC inhibitors, which prevent pathological
cardiac remodeling.10 HDAC3 has been implicated in the
control of cardiac lipid metabolism.11 In contrast, the 4 class
IIa HDACs (HDACs 4, 5, 7, and 9) contain a large N-terminal
regulatory domain and a catalytic domain with weak activity.7
These HDACs exert their functions through recruitment of
class I HDACs and other corepressors to transcription factors,
such as myocyte enhancer factor (MEF)2.
The response of the heart to biomechanical stress and other
forms of pathological signaling is governed by the class II
HDACs, HDAC5 and -9, which serve as signal-responsive
repressors of the MEF2 transcription factor.6 In the unstimu-
lated state, these HDACs interact with MEF2 and repress the
transcription of MEF2 target genes, whereas on activation of
intracellular signaling pathways involving calcium, calmod-
ulin-dependent protein kinase or protein kinase D, these
HDACs become phosphorylated, triggering their nuclear
export and the consequent activation of MEF2 target genes.
Consistent with the roles of HDAC5 and -9 as repressors of
pathological MEF2 activity, male mice lacking these HDACs
display enhanced MEF2 activity and heightened sensitivity to
cardiac stress.12,13
In the present study, we investigated the potential involve-
ment of the MEF2/class II HDAC pathway in post-MI
remodeling in male and female mice. Whereas male mice
lacking HDAC5 or -9 were hypersensitive to the pathological
effects of MI, we found, unexpectedly, that female mice
lacking HDAC5 and -9 were protected against pathological
remodeling of the heart following MI. In the absence of
HDAC5 or -9, there is a pronounced increase in expression of
the ER gene, which contains essential MEF2 binding sites in
its promoter. In addition, HDAC5 and -9 directly interact
with ER to repress transcriptional activation of the receptor
by estrogen. Upregulation of ER signaling in female mice
mutant for either HDAC5 or -9 dramatically diminishes
cardiac dysfunction and deleterious left ventricular remodel-
ing following MI. This protection appears to be due, at least
in part, to neoangiogenesis in the infarcted region via upregu-
lation of the ER target gene vascular endothelial growth
factor (VEGF)a. These findings reveal a key role for MEF2
and class II HDACs in the regulation of cardiac ER signaling
and the mechanisms underlying the cardioprotective effects
of estrogen.
Methods
An expanded Methods section is available in the Online Data
Supplement at http://circres.ahajournals.org.
Surgical Procedures and Echocardiography
All animal protocols were approved by the Institutional Animal Care
and Use Committee of the University of Texas Southwestern
Medical Center. Adult age matched HDAC9 knockout (KO),
HDAC5 KO mice, and wild-type (WT) mice of either sex received
a MI as described before.14 Sham-operated animals underwent the
same procedure without occlusion of the left coronary artery. At 4
weeks of age, mice were either sham-operated or ovariectomized and
either left untreated or treated with 17-estradiol (0.16 g per day)
for 4 weeks as described.15 Three weeks following MI, echocardi-
ography was performed in conscious mice using the fully digital
Vingmed System (GE Vingmed Ultrasound, Horten, Norway) and a
11.5-MHz linear array transducer as previously described.16 All
surgeries and subsequent analyses were performed in a blinded
fashion for genotype.
Infarct Size
To measure the infarct size 3 weeks post-MI, the heart was excised,
and the left ventricles (LVs) were cut from apex to base into 3
transverse sections. Five-micron sections were cut and stained with
Masson’s trichrome. Infarct length was measured along the endocar-
dial and epicardial surfaces from each of the cardiac sections, and the
values from all specimens were summed. Infarct size (in percentage)
was calculated as percentage of infarcted LV versus total LV
circumference. Values represent the average of 3 slides per animal.17
Histology and Histochemistry
After collection, heart tissue was either cryoembedded or incubated
for 30 minutes in Krebs buffer (118 mmol/L NaCl, 4.7 mmol/L KCL,
1.2 mmol/L KH2PO4, 1.2 MgSO4, 25 mmol/L NaHCO3, 11 mmol/L
glucose) to arrest the heart in diastole, fixed in 3.7% paraformalde-
hyde, and embedded in paraffin. Sections were stained with hema-
toxylin/eosin to visualize infarcted area (n3 to 6 in each group). To
examine the capillary density, all sections were incubated with
biotinylated Griffiona simplicifolia lectin (Vector Laboratories,
United Kingdom) for 2 hours at room temperature, as described
previously.18 The number of capillaries was counted under micros-
copy for 5 random fields in the remote, border zone, or infarcted
region of each longitudinal slices in both WT and HDAC9 KO
female animals post-MI.
RNA Extraction and RT-PCR Analysis
Total RNA from the infarcted area, including the border zone region,
was isolated using TRIzol (Invitrogen). A 10-g aliquot representa-
tive of 3 animals per sample group was then analyzed on Affymetrix
U74Av2 microarrays. A subset of differentially expressed RNAs was
further characterized by either semiquantitative PCR or quantitative
real-time PCR (see Online Table I for primer sequences).
In Situ Hybridization
Section in situ hybridization was performed on fresh-frozen tissue 4
days after either sham surgery or MI as described,19 with some minor
modifications because of the use of cryosections. The coding regions
of VEGFa and VEGFr2 were subcloned into pCDNA, linearized, and
transcribed as follows: antisense VEGFa, BamHI, and T3; antisense
VEGFr2, NotI, and T7 (generously provided by Dr T. Sato, Univer-
sity of Texas Southwestern Medical Center).
Non-standard Abbreviations and Acronyms
AF activation function
EMSA electrophoretic mobility-shift assay
ER estrogen receptor
ERE estrogen response element
GST glutathione S-transferase
HDAC histone deacetylase
KO knockout
LV left ventricle
MEF2 myocyte enhancer factor 2
MI myocardial infarction
TSA trichostatin A
VEGF vascular endothelial growth factor
WT wild type
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Electrophoretic Mobility-Shift Assays
Oligonucleotides corresponding to the conserved MEF2-binding site
in the ER regulatory region and the mutated MEF2-binding sites
were used to detect MEF2 binding (see Online Table II for primer
sequences). Annealed oligonucleotides were radiolabeled with
[32P]dCTP using the Klenow fragment of DNA polymerase and
purified using G50 spin columns (Roche). Nuclear cell extracts were
isolated from COS-1 cells that were transfected with pcDNAMYC-
MEF2C. Reaction conditions of the gel mobility-shift assays were
previously described.20
Generation of ER Reporter Constructs
A mouse genomic DNA fragment covering either the region from
3990 to 1 relative to the ER transcription initiation site was
isolated from genomic DNA C57Bl6. These ER promoter frag-
ments were cloned into pGL2 luciferase vector as a KpN/Nhe
fragment. Mutations of the MEF2 sites were introduced into the
sequence by PCR-based site-directed mutagenesis. All constructs
were verified by DNA sequence analysis.
Cell Culture, Transfection, and Luciferase Assays
MYC- and FLAG-tagged derivatives of MEF2C, asHDAC9, and
asHDAC5 and the signal-resistant counterparts (S259/498A, adH-
DAC5 SA) have been described.6,21 Primary rat cardiomyocytes
were prepared as described.22 Eighteen hours after plating, cells were
infected with adenovirus for 2 hours and subsequently cultured in
serum-free medium for 48 hours before collection. Both COS-1 and
HeLa cells were maintained in DMEM with FBS (10%), L-glutamine
(2 mmol/L), and penicillin-streptomycin, and transfections were
performed as described previously.6 COS-1 cells were transfected
with pcDNAMYC-MEF2C to obtain nuclear cell extracts for elec-
trophoretic mobility-shift assays (EMSAs). HeLa cells were trans-
fected with a reporter construct containing 3 estrogen response
elements (3ERE-Luc), full-length ER, and increasing concentra-
tions of either HDAC5 and -9 and -galactosidase (internal control)
reporter plasmids using Fugene 6 (Stratagene) according to the
instructions of the manufacturer. Luciferase activity is reported as
the fold induction compared with that of empty 3ERE-Luc alone.
Relative promoter activities are expressed as luminescence relative
units normalized for -galactosidase expression in the cell extracts.
Glutathione S-Transferase Pull Down
Glutathione S-transferase (GST)-ER was generated by subcloning
PCR amplified fragment into EcoRI and XhoI sites of the pGEX-KG
vector, whereas GST-dHDAC9 (aa131–586) was subcloned in the
pGEX-KG vector as a XbaI-XhoI fragment. The GST pull down was
performed as described previously.6
Statistical Analysis
Data are shown as meansSD. Comparison between 2 groups were
analyzed by the 2-tailed Student’s t test. Values of P0.05 were
considered statistically significant.
Results
The Absence of HDAC5 and -9 Protects Female
Mice Against Post-MI Cardiac Remodeling
To explore the potential influence of class II HDACs on
gender-specific responses of the heart to injury, we compared
the cardiac remodeling responses of male and female WT and
HDAC5 and -9 KO mice following MI. Survival up to 3
weeks after MI was comparable in WT males and females
(63% versus 65%, respectively). Whereas a dramatic de-
crease in survival was evident in HDAC5 and -9 mutant
males (36% and 40%, respectively), female mice deficient for
HDAC5 and -9 displayed remarkably improved postinfarc-
tion survival (85% and 83%, respectively) especially in the
first week after the insult (Figure 1A).
Echocardiography 3 weeks after MI surgery indicated that
left ventricular diastolic dimension, left ventricular systolic
dimension, and fractional shortening worsened severely in
both male and female WT mice, whereas there were no
differences in the sham-operated animals. The loss of cardiac
function was even more dramatic for male HDAC mutant
Figure 1. Female class II HDAC KO mice are protected against
post-MI cardiac remodeling. A, Post-MI mortality was compara-
ble between male and female WT mice. Whereas male HDAC5
and -9 mutant animals had an elevated mortality compared to
WT, females lacking HDAC5 or -9 showed an increase in sur-
vival after MI (WT males, n13; WT females, n17; HDAC5 KO
males, n15; HDAC5 KO females, n16; HDAC9 KO males,
n16; HDAC9 KO females, n16). B, Cardiac function was
measured by echocardiography 3 weeks after permanent left
coronary artery ligation. The data demonstrate progressive dila-
tion and loss of contractile function in WT mice as indicated by
left ventricular systolic dimension (LVIDs) and fractional shorten-
ing, whereas the loss of cardiac function was substantially
attenuated in female HDAC5 and -9 KO mice (n5 in sham
groups; n9 to 10 in MI groups). *P0.05 vs corresponding WT
group. C, The infarct size 3 weeks post-MI expressed as a frac-
tion of the total cross-sectional circumference of the LV indi-
cates that the infarct size in HDAC5 and -9 KO females is signif-
icantly smaller than the infarct size in WT females (34% and
37% vs 55% in WT, n4). *P0.05 vs corresponding WT
group. D, Hematoxylin/eosin staining on transverse section 3
weeks post-MI shows the infarct of HDAC9 KO females to be
nontransmural because of the presence of an additional layer of
surviving cells at the epicardial surface of the infarcted area.
The region in the box is enlarged in the lower panel. Scale bars:
top, 2 mm; bottom, 20 m.
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mice (data not shown). However, both parameters were
significantly preserved in HDAC5 and HDAC9 mutant fe-
males compared to WT females, indicative of better-
maintained cardiac function (Figure 1B, Online Table III, and
Online Figure I). The fact that genetic deletion of both class
II HDACs leads to the protection in females points to a
threshold of class II HDACs below which there is a protective
effect.
Three weeks after MI, morphometric analysis indicated the
presence of cardiac hypertrophy and concomitant signs of
cardiac failure, such as an increase in lung weight, in WT
females, whereas this pathological remodeling response was
lacking in the HDAC5 and -9 mutant females (Online IV,
only shown for HDAC9 KO females). Infarct size measure-
ments as percentage of LV circumference indicated 55% of
the LV to be affected by the infarct in WT females, whereas
the infarct accounted for 37% and 34% of the LV in HDAC5
and -9 KO females, respectively (Figure 1C). Histological
examination of the infarcted area clearly indicated the pres-
ence of a distinct layer of surviving cardiomyocytes at the
epicardial surface of the infarcted region in the HDAC9 KO
females (Figure 1D). Because of the presence of this addi-
tional layer of muscle cells, the integrity of the infarcted area
was better maintained after MI and likely prevented the heart
from dilating to the same extent as in the WT mice, which
results in a better maintenance of cardiac function post-MI.
Upregulation of VEGFa in the Infarcted Region of
HDAC9 KO Females
Gene expression analysis to further explore the mechanistic
basis of gender-specific cardioprotection in HDAC mutant
females indicated that a collection of genes implicated in ER
signaling was expressed at significantly higher levels in the
infarcted areas of the HDAC9 KO females compared to their
gender-matched WT littermates (Online Table V). Because of
the obvious restriction of the cardioprotective effect of class
II HDAC deletion to females, the upregulation of genes
involved in ER signaling, and previous reports on the in-
Figure 2. Enhanced angiogenic response
in infarcted region of HDAC9 mutant
females 3 weeks post-MI. A, Real-time
PCR for angiogenic factors indicates an
increased angiogenic response in the
infarcted region of the HDAC9 KO
females vs the WT females. Data are rep-
resented as fold change compared to WT
animals. B, In situ hybridization analysis
revealed an increase in both VEGFa and
its endothelial cell surface receptor
VEGFr2 at the border zone of the
infarcted region 4 days post-MI, which is
more pronounced in the HDAC9 KO
females. Red square indicates the
enlarged area shown on the right. Scale
bars: 40 m. C, Representative sections
stained for lectin show an equal distribu-
tion of capillaries surrounding cardiomyo-
cytes in the noninfarcted, remote areas,
whereas the ischemic region shows irreg-
ular patterning of vasculature with addi-
tional and enlarged vessels in the border
zone and the infarcted region of the
HDAC9 mutant females compared to the
WT females. Scale bars: 20 m. D, Semi-
quantitative analysis of capillary density
in the myocardium indicates there to be
no difference in number of vessels in the
remote region between WT and HDAC9 KO females. However, HDAC9 KO females show an increase in vessel density in the border
zone compared to WT females. The capillary count of these sections is expressed as number of vessels per microscopic field (n4 to
6; meansSD). *P0.05 vs WT group.
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volvement of HDACs in the ER signaling pathway,23–27 we
speculated that class II HDAC removal led to an increase in
expression of ER target genes.
One of the beneficial effects of estrogen on the cardiovas-
cular system is to improve myocardial perfusion by the
formation of new capillaries and by the enlargement of
preexisting collateral vessels, when the myocardium is de-
prived of blood.28–31 One key regulator of this proangiogenic
response is the ER target gene VEGFa, which encodes an
extracellular ligand for its corresponding endothelial recep-
tors flt-1 (Fms-related tyrosine kinase 1, or VEGF receptor 1)
and flk-1 (fetal liver kinase 1, or VEGF receptor 2).2,32–35
Real-time PCR analysis indicated numerous angiogenic fac-
tors to be more highly expressed in the infarcted area of the
HDAC9 KO females compared to WT females. VEGFa and
its receptors (VEGFr1 and VEGFr2) were upregulated most
dramatically (68-, 12-, and 20-fold versus WT, respectively)
(Figure 2A). This observation is consistent with the fact that
VEGFa induces expression of its receptors to create a positive
feed-forward loop allowing endothelial cells to become re-
sponsive to and activated by VEGF.33 The expression levels
of the angiogenic factors tested did not differ in the sham-
operated animals between either sex of WT and HDAC9 KO
animals, nor did they differ between male and female
HDAC9 KO mice (data not shown).
During the first few days following MI there is a neoan-
giogenic response within the infarcted tissue. In situ hybrid-
ization 4 days after MI indicated that VEGFa and VEGFr2
expression was significantly induced in the border zone,
which was even more pronounced in the HDAC9 KO females
(Figure 2B). This indicates that removal of class II HDACs in
females increases the expression of VEGFa and its down-
stream receptors, which likely promotes cardioprotection
after ischemic damage.
To visualize the vasculature, we used Griffonia Simplici-
folia lectin I (GS-I) as an endothelial surface marker.18 There
was a regular distribution of capillaries around cardiomyo-
cytes in both sham-operated groups, with no detectable
differences is vessel density. Three weeks after MI, the border
zone of the infarcted area contained regions of low vascular-
ity in the WT animals, which was even more decreased in the
infarct. However, both the border zone and the infarcted
region of the HDAC9 KO females appeared to be highly
vascular, with enlarged, thin-walled vessels (Figure 2C). The
number of capillaries that was counted in the remote, border
zone, or infarcted region of longitudinal slices in both WT
and HDAC9 KO female animals post-MI indicated there to
be no difference in vessel density in the remote region,
whereas this number was significantly increased in the border
zone of the HDAC9 KO females (Figure 2D). These findings
suggest that the cardioprotection observed in HDAC5 and -9
mutant females is attributable, at least in part, to an increase
in vessel formation post-MI, which might involve VEGFa,
because prolonged VEGFa expression in the myocardium
results in a high density of vessels with enlarged lumens.32
Cardioprotective Effect Dependent on Estrogen
Based on the fact that the cardioprotective effect after MI in
the absence of class II HDACs appeared to be restricted to
females, and the known interaction between HDACs and
ER, we speculated this gender-dependent response in the
class II HDAC-null background to be attributable to an
enhancement of cardiac ER signaling. To explore this hy-
pothesis, we subjected HDAC9 mutant females at 4 weeks of
age to ovariectomy, followed by supplementation of a phys-
iological dose of estrogen or a placebo pellet before we
induced MI. Ovariectomy in these females before MI resulted
in a thin dilated infarcted region, whereas additional estrogen
supplementation again inhibited the infarct to become trans-
mural (Figure 3A). In line with the functional data, we
observed an increase in post-MI mortality in the mutant
ovariectomized group, although this increase was abolished
Figure 3. Cardioprotection regulated by the effect
of estrogen. A, Histological sections show that
ovariectomy in the HDAC9 females ablates the
protective effect on cardiac remodeling, whereas
supplementation of estrogen restores the protec-
tive effect 3 weeks post-MI. Scale bars: 40 m. B,
Post-MI mortality in ovariectomized (ovex) females
was comparable to the post-MI mortality seen in
WT females. Supplementation of estrogen in ovari-
ectomized HDAC9 KO females was able to largely
restore the protective effect (n5 to 10). C, Car-
diac function was measured by echocardiography
3 weeks after MI. The data demonstrate more dila-
tion and loss of contractile function in HDAC9 KO
females after ovariectomy as indicated by left ven-
tricular systolic dimension (LVIDs) and fractional
shortening, whereas these effects were substan-
tially attenuated after estrogen supplementation
(n5 in sham group; n7 to 10 in MI groups).
*P0.05 vs corresponding HDAC9 KO post-MI
group.
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Figure 4. Cardiac expression of ER is regulated by MEF2 and class II HDACs. A, Cross-species conservation of genomic sequences
upstream of the ER gene is shown at the top. Sequence of putative MEF2 transcription factor-binding sites (in boxes) in the promoter
of the mouse ER gene. Numbers in brackets refer to location of the MEF2 site relative to the ATG start codon for ER. B, EMSA for
binding of MEF2C to the putative MEF2 sites of the ER promoter using nuclear extracts from COS-1 cells transfected with a MYC-
MEF2C expression plasmid and the radiolabeled MEF2 site. The MEF2-DNA complex was supershifted by anti-MYC antibody and was
abolished in the presence of an excess of the unlabeled cognate DNA sequence or the prototypical MEF2 site from the muscle creatine
kinase enhancer as a competitor, whereas a mutant sequence that did not bind MEF2C failed to compete for MEF2C binding. C, Lucif-
erase reporter experiments using an upstream promoter fragment of the ER gene indicates that MEF2 can induce transcriptional
activity, which is enhanced in the presence of myocardin. Mutational analysis indicates that the MEF2 site 770 bp upstream of the tran-
scriptional start is responsible for the MEF2 responsiveness of the ER gene. D, Real-time PCR analysis of ER expression in nonin-
fected neonatal rat cardiomyocytes compared with cells infected with AdCMV-gal or AdCMV-asHDAC5 or asHDAC9 indicates that
both asHDAC5 and asHDAC9 increases ER expression in myocytes in a dose-dependent manner. MOI indicates multiplicity of infec-
tion. Additionally, adenoviral overexpression of MEF2C (AdMEF2C) is capable of inducing ER expression, whereas titrating in a signal
resistant form of HDAC5 (AdHDAC5 SA) reduces this induction. E, Real-time PCR analysis of ER expression in cardiac samples of
WT, HDAC5 and HDAC9 KO animals shows an in vivo upregulation of ER expression in the absence of HDAC5 and -9 compared to
WT. *P0.05 compared to corresponding WT male or female.
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in the presence of estrogen supplementation (Figure 3B).
Although ovariectomy at baseline had no overt effect on
cardiac function in the mutant females, MI phenocopied the
decrease in cardiac function present in WT females after MI,
whereas supplementation of a physiological dose of estrogen
in these animals resulted in a comparable resistance to cardiac
dysfunction post-MI, as seen in the HDAC9 KO females
(Figure 3C and Online Table VI). However, short-term
estrogen supplementation in male HDAC9 KO animals was
unable to reverse the remodeling and induce the protective
effect seen in females (data not shown). It is likely that this is
because of the ongoing adverse cardiac remodeling that took
place because of the extended absence of HDAC9 in these
males.12,13 The levels of circulating estrogen did not differ at
baseline between WT and HDAC9 mutant females (data not
shown).
These data indicate that the reduction of the maladaptive
alterations of both the remote myocardium and the infarcted
area in the postinfarcted heart of HDAC9 KO females is
likely attributable to an enhancement of estrogen signaling
because ovariectomy in HDAC9 KO females results in a
post-MI response comparable to WT females and subsequent
addition of estrogen can recapitulate the cardioprotective
effect before ovariectomy.
Regulation of ER Expression by MEF2 and Class
II HDACs
Class II HDACs associate with MEF2 and inhibit MEF2-
dependent transcription.36,37 To determine whether loss of
HDAC5 and -9 might enhance cardiac ER signaling through
upregulation of the receptor isoforms via MEF2, we scanned
the 5 flanking regions of both the ER and ER genes and
identified 2 conserved putative MEF2 binding sites located
between 3990 and 1 bp relative to the translation initia-
tion codon of the ER gene (Figure 4A). EMSA was used to
check for binding of MEF2C to the putative MEF2 sites of the
ER promoter using nuclear extracts from COS-1 cells
transfected with a MYC-MEF2C expression plasmid and the
radiolabeled MEF2 site. Both MEF2 consensus sequences
bound MYC-tagged MEF2C avidly, with the highest binding
seen for the sole perfect MEF2 binding sequence (site 2). The
MEF2-DNA complex was supershifted by anti-MYC anti-
body and was abolished in the presence of an excess of the
unlabeled cognate DNA sequence or the prototypical MEF2
site from the muscle creatine kinase enhancer,38 which was used
as a competitor, whereas a mutant sequence that did not bind
MEF2C failed to compete for MEF2C binding (Figure 4B).
Reporter assays transfecting the 4-kb enhancer fragment
fused to luciferase into COS-1 cells indicated this region to be
responsive to MEF2, which was further enhanced by the
MEF2 coactivator myocardin. Mutating MEF2 site 1 was
unable to abrogate MEF2 transcriptional activation, whereas
a comparable mutation of site 2 completely abolished tran-
scription, indicating that MEF2 responsiveness is dependent
on the MEF2 site located 770 bp upstream of the transcrip-
tional start of the ER gene (Figure 4C).
To determine whether the expression of ER in cardio-
myocytes is regulated by MEF2 and its interaction with class
II HDACs, we infected neonatal rat ventricular myocytes
with increasing amounts of an adenovirus expressing anti-
sense HDAC5 or -9. Real-time PCR analysis indicated a
dose-dependent increase in ER expression with loss of these
class II HDACs (Figure 4D). Additionally, adenoviral over-
expression of MEF2C induced the expression of ER, and
this effect was blunted in the presence of an increasing
amount of a signal-resistant HDAC5 mutant, referred to as
HDAC5S/A, which functions as a MEF2 super-repressor
(Figure 4D).6 Consistent with the conclusion that HDAC5
and -9 negatively regulate the expression of ER in vivo,
ER expression was significantly upregulated in cardiac
samples of both HDAC5 and -9 KO animals, whereas ER
expression levels were unchanged (Figure 4E and data not
shown). We conclude that MEF2 binds directly to the
regulatory region of the ER gene and is responsible for the
increased expression of ER in the absence of either class II
HDAC5 or -9.
Figure 5. The MEF2 binding domain of class II HDACs directly
interact binding with ER. A, Either GST alone or GST-ER was
expressed in E coli, conjugated to glutathione-agarose beads,
and incubated with the indicated [35S]methionine-labeled
HDACs. Although the class II HDACs 4, 5, and 9 all bind,
HDAC1 failed to interact with ER in this assay. B, To map the
domain of interaction, GST alone or GST-ER was incubated
with the indicated [35S]methionine-labeled HDAC5 deletion
mutants. The HDAC mutants lacking the MEF2 binding domain
failed to interact with ER in this assay.
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Class II HDACs Regulate ER Signaling by Direct
Interaction With ER
Because HDAC1 and 4 have been shown to downregulate the
transcriptional activity of ER by directly interacting with the
receptor,27,39 we aimed to determine whether HDAC5 and -9
could also interact with the receptor. For this purpose,
full-length ER was fused to GST, expressed in Escherichia
coli, and tested for the ability to associate with in vitro-translated
HDAC4, -5, -9, and -1. Whereas the class II HDACs 4, 5, and 9
interacted with ER, we were unable to detect an interaction
with HDAC1, a class I HDAC (Figure 5A).
To map the region of class II HDACs that mediates the
association with ER, we assessed the capacities of a series of
HDAC5 deletion mutants to associate with GST-ER (Figure
5B). Deletion of residues from amino acid 260 to the carboxyl
terminus of HDAC5 had no effect on ER binding. Similarly, an
N-terminal deletion mutant lacking the CtBP binding domain
(mutant 51-C) interacted with ER, whereas deletion mutants
lacking the MEF2 binding domain failed to bind ER.
To determine which region on ER was able to interact
with class II HDACs, we used GST-HDAC5 (aa131–586)
and generated a series of ER deletion mutants. ER contains
the following functional domains: a hormone-independent
transcription function domain (AF-1); a DNA-binding do-
main; a hinge region containing 3 nuclear localization se-
quences that mediate the translocation of the receptor from
cytosol to nucleus; and a conserved ligand-binding domain,
possessing dimerization and hormone-dependent activation
functions (activation function [AF]-2).40 Whereas an
N-terminal deletion mutant lacking the ligand-binding do-
main was able to interact with HDAC5, this interaction was
absent using N- and C-terminal deletion mutants lacking the
nuclear localization sequence domain. We therefore conclude
that the MEF2 binding domain in class II HDACs directly
interacts with ER by binding to the nuclear localization
sequence domain (Figure 6A).
Because class II HDACs are known to interact with the
nuclear receptor corepressors SMRT and N-CoR, we pre-
dicted that the association of these HDACs with the ER
would inhibit ER function by repressing its transcriptional
activity. Indeed, transfection experiments in HeLa cells
showed significant suppression of the ER-dependent reporter
3ERE-Luc reporter with both HDAC5 and -9 in a
concentration-dependent manner (Figure 6B). Combined
treatment of cells with ER and the HDAC inhibitor tricho-
statin A (TSA) resulted in robust synergistic activation of
ER transcriptional activity (Figure 6C). Together, these
findings suggest that class II HDACs are capable of direct
interaction with ER and repress the transcriptional activity
of the receptor.
Discussion
Estrogens protect the female heart against cardiovascular
disease.3 Through its nuclear receptor, estrogen can attenuate
left ventricular hypertrophy, enhance angiogenesis, improve
contractility, and prevent pathological cardiac remodeling
after ischemic insult. Our results show that class II HDACs
play a key role in the regulation of cardiac ER signaling and
that removal of either HDAC5 or -9 elicits a cardioprotective
mechanism in female mice that is dependent on signaling
through ER (Figure 7). Class II HDACs associate with
MEF2 and inhibit MEF2 dependent transcription.13,36 This
Figure 6. Class II HDACs repress the transcrip-
tional binding activity of ER through direct bind-
ing of the MEF2 domain with the N terminus of
ER. A, To map the domain of interaction, GST
alone or GST-HDAC5 was incubated with the
indicated [35S]methionine-labeled ER deletion
mutants. The ER mutant lacking the nuclear
localization sequences failed to interact with
class II HDAC5 in this assay. B, HeLa cells were
transfected with 3ERE-Luc, full-length ER, and
increasing concentrations of either HDAC5 and
-9 and -galactosidase (internal control) reporter
plasmids. Luciferase activity is reported as the
fold induction relative to empty 3ERE-Luc alone.
ER induces luciferase activity which is dose-
dependently decreased by the presence of either
HDAC5 or -9. C, Titrating in either HDAC5 or -9
both severely reduces the transcriptional activity,
whereas HDAC inhibition by TSA, a pharmaco-
logical HDAC inhibitor, strongly enhances the
transcriptional activity of ER.
Figure 7. Model for the control of ER expression
and cardioprotection by MEF2 and class II
HDACs. Class II HDACs repress ER expression
through a MEF2 response element (MRE)
upstream of the ER gene. Additionally, class II
HDACs directly interact with ER and repress the
transcriptional activity of the receptor in the pres-
ence of its ligand, estrogen (E2). Class II HDAC
inhibition increases the cardioprotective effect of estrogen by both increasing the level of ER and the transcriptional activity of the
receptor. ER acts through an ERE in the promoter of the VEGF gene and other genes encoding angiogenic factors.
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phenomenon applies not only to post-MI remodeling, because
the age dependent cardiac remodeling seen in male HDAC5
and -9 mutant animals is also largely absent in female
littermates (Online Figure III). Our data demonstrate the ER
gene to be under control of MEF2 and to be upregulated in the
absence of either HDAC5 or -9, providing a mechanism to
account for the cardioprotection observed in HDAC5 and -9
mutant females.
Modulation of ER Activity by HDACs
In response to pathological signals, class II HDACs are
shuttled from the nucleus to the cytoplasm, allowing for
activation of MEF2-dependent gene expression (reviewed
elsewhere41). Thus, our results predict that cardiac stress
should induce ER expression. In line with our predictions,
ER expression has been shown to be increased in both male
and female human hypertrophic and end-stage failing
hearts.42,43
In addition to regulating gene expression through MEF2,
class II HDACs interact with other transcriptional regulators.
SMRT and N-CoR interact with nuclear receptors and repress
the activity of the receptors through the recruitment of either
class I or class II HDACs.44 Transcriptional repression of
N-CoR and SMRT is mediated by multiple repression do-
mains, which engage distinct HDAC complexes. Whereas
class I HDACs interact with SMRT and N-CoR indirectly
through mSin3, class II HDACs directly interact with SMRT
and N-CoR through a different repressor domain.45 Kraus and
colleagues have shown that ER, but not ER, is a target for
acetylation by p300 and have identified acetylation as mod-
ulator of the ligand-dependent gene regulatory activity of
ER.46 Besides the fact that the recruitment of HDACs to the
ER would promote chromatin condensation of ER target
genes, the transcriptional activity and estrogen sensitivity of
ER is enhanced by p300-induced acetylation of the receptor
itself, which can be increased by TSA.46 In this study, we
show that, in addition to this distinct manner of interaction
between class I and II HDACs with the SMRT/N-CoR
corepressor complex, and in contrast to class I HDACs, class
II HDACs directly interact with ER. These findings reveal a
substantial difference between nuclear receptor corepressor–
HDAC complexes involving either class I or II HDACs and
provide a rationale for a distinct, tissue-specific recruitment
of HDACs by the SMRT/N-CoR complex to regulate the
transcriptional activity of ER.
Modulation of Angiogenesis by Estrogens
Irrespective of whether class II HDAC removal enhances
cardiac ER signaling through upregulation of the receptor,
through an increase in transcriptional activity of the receptor,
or a combination of both, our findings have important
implications because of the beneficial effects of ER signaling
on the heart. Estrogens are capable of inducing angiogenesis
both in vitro and in vivo47 and have been postulated to induce
myocardial revascularization post-MI. Although the mecha-
nisms involved in the proangiogenic effects of estrogen are
probably multifactorial, upregulation of VEGFa, its receptors,
and additional angiogenic proteins is clearly involved.48–52
Estrogen is able to regulate VEGFa expression by increasing
the recruitment of ER and p300 to Sp1 bound to the
promoter of the VEGFa gene.53 Recruitment of hypoxia-
inducible factor 1, another key regulator of the transcrip-
tional response during oxygen deprivation, is also required
for the increase in VEGFa expression in response to estro-
gen.53 The requirement of both hypoxia-inducible factor 1
and ER to induce VEGFa expression would be in line with
our data, because we were unable to detect a significant
difference at baseline in expression level of angiogenic
factors in HDAC mutant mice, whereas post-MI, the absence
of class II HDACs caused an exaggerated expression of
angiogenic factors in females, with VEGFa being the most
dominant. We speculate that the exaggerated VEGFa expres-
sion in the border zone of the infarcted area on removal of
class II HDACs enables the endothelial cells of the existing
coronary network to branch and thereby improve the perfu-
sion of the ischemic myocardial tissue, preventing infarcts
from becoming transmural. However, the protective effects of
estrogen include many facets of heart disease. Estrogen
inhibits the development of pathological hypertrophy and
changes the expression of a number of cardioprotective genes
such as nitric oxide synthase and heat shock proteins54–56 and
alters a number of genes involved in metabolism such as
those encoding lipoprotein lipase, prostaglandin D2 synthase,
and PGC-1 (peroxisome proliferator-activated receptor 
coactivator 1).55 The most highly upregulated gene in the
HDAC9 mutant females compared to WT females was
PPARBP (peroxisome proliferator-activated receptor binding
protein) (TRAP220), a transcriptional coactivator that di-
rectly enhances the activity of the ER.57 How this cofactor
might contribute to cardioprotection remains to be deter-
mined. Conceivably, the protective effect seen in the mutant
class II HDACs females reflects the net effect of a combina-
tion of these responses.
HDAC Inhibitors and the Heart
Reduced post-MI remodeling through enhanced angiogenesis
is only one of the many cardioprotective responses induced
by ER signaling. Our data imply that removal of class II
HDACs likely constitutes a more general effect of cardiopro-
tection through enhancement of this signaling cascade. Inter-
estingly, HDAC inhibitors have shown efficacy in humans
and animal studies in suppressing tumor cell growth and
hypertrophy.58,59 Although to date, 1 in vitro study reported
on selective inhibition of class II HDACs,60 the in vivo
efficacy and utility of such inhibitors needs to be tested.
Future studies will provide insight into whether it is possible
to enhance ER signaling through the use of HDAC inhibitors,
and, if so, whether this will not only increase estrogen-
dependent cardioprotection by the ER but also the neuro- and
musculo-protective effects of ER signaling. Finally, increas-
ing the transcriptional activity of the ER by relieving it from
the repressive effects of class II HDACs may prove beneficial
in numerous cardiac pathologies because of the broad spec-
trum of beneficial cardiovascular effects of ER signaling.
Sources of Funding
Work in the laboratory of E.N.O. was supported by grants from the
NIH, the Donald W. Reynolds Cardiovascular Clinical Research
van Rooij et al Class II HDACs and ER-Mediated Cardioprotection 163
 at Vrije on July 11, 2011http://circres.ahajournals.org/Downloaded from 
Center, the Robert A. Welch Foundation, and the Leducq Founda-
tion. Additional support was received by European Union Contract
no. LSHM-CT-2005-018833/EUGeneHeart and a VIDI award 917-
863-72 from The Netherlands Organization for Health Research and
Development (to L.J.D.W.). E.v.R. received funding from a Scientist
Development Grant from the American Heart Association.
Disclosures
None.
References
1. Roenicke V, Leclair S, Hoffmann A, Becker M, Szado T, Kirsch T, Stoss
O, Nave BT, Henkel T. Emerging therapeutic targets in chronic heart
failure: part II. Expert Opin Ther Targets. 2003;7:49–59.
2. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang
J, Homma S, Edwards NM, Itescu S. Neovascularization of ischemic
myocardium by human bone-marrow-derived angioblasts prevents car-
diomyocyte apoptosis, reduces remodeling and improves cardiac
function. Nat Med. 2001;7:430–436.
3. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovas-
cular gender differences. Science. 2005;308:1583–1587.
4. Mendelsohn ME, Karas RH. The protective effects of estrogen on the
cardiovascular system. N Engl J Med. 1999;340:1801–1811.
5. Schultz JR, Petz LN, Nardulli AM. Cell- and ligand-specific regulation of
promoters containing activator protein-1 and Sp1 sites by estrogen
receptors alpha and beta. J Biol Chem. 2005;280:347–354.
6. McKinsey TA, Zhang CL, Lu J, Olson EN. Signal-dependent nuclear
export of a histone deacetylase regulates muscle differentiation. Nature.
2000;408:106–111.
7. Haberland M, Montgomery RL, Olson EN. The many roles of histone
deacetylases in development and physiology: implications for disease and
therapy. Nat Rev Genet. 2009;10:32–42.
8. Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X,
Hill JA, Richardson JA, Olson EN. Histone deacetylases 1 and 2 redun-
dantly regulate cardiac morphogenesis, growth, and contractility. Genes
Dev. 2007;21:1790–1802.
9. Antos CL, McKinsey TA, Dreitz M, Hollingsworth LM, Zhang CL,
Schreiber K, Rindt H, Gorczynski RJ, Olson EN. Dose-dependent
blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors.
J Biol Chem. 2003;278:28930–28937.
10. Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T, Floss T,
Goettlicher M, Noppinger PR, Wurst W, Ferrari VA, Abrams CS, Gruber
PJ, Epstein JA. Hdac2 regulates the cardiac hypertrophic response by
modulating Gsk3 beta activity. Nat Med. 2007;13:324–331.
11. Montgomery RL, Potthoff MJ, Haberland M, Qi X, Matsuzaki S,
Humphries KM, Richardson JA, Bassel-Duby R, Olson EN. Maintenance
of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin
Invest. 2008;118:3588–3597.
12. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN.
Histone deacetylases 5 and 9 govern responsiveness of the heart to a
subset of stress signals and play redundant roles in heart development.
Mol Cell Biol. 2004;24:8467–8476.
13. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class
II histone deacetylases act as signal-responsive repressors of cardiac
hypertrophy. Cell. 2002;110:479–488.
14. van Rooij E, Doevendans PA, Crijns HJ, Heeneman S, Lips DJ, van
Bilsen M, Williams RS, Olson EN, Bassel-Duby R, Rothermel BA, De
Windt LJ. MCIP1 overexpression suppresses left ventricular remodeling
and sustains cardiac function after myocardial infarction. Circ Res. 2004;
94:18–26.
15. Srivastava S, Weitzmann MN, Kimble RB, Rizzo M, Zahner M, Mil-
brandt J, Ross FP, Pacifici R. Estrogen blocks M-CSF gene expression
and osteoclast formation by regulating phosphorylation of Egr-1 and its
interaction with Sp-1. J Clin Invest. 1998;102:1850–1859.
16. Harrison BC, Kim MS, van Rooij E, Plato CF, Papst PJ, Vega RB,
McAnally JA, Richardson JA, Bassel-Duby R, Olson EN, McKinsey TA.
Regulation of cardiac stress signaling by protein kinase d1. Mol Cell Biol.
2006;26:3875–3888.
17. Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J,
Ishibashi M, Kubota T, Egashira K, Takeshita A. Pioglitazone, a per-
oxisome proliferator-activated receptor-gamma agonist, attenuates left
ventricular remodeling and failure after experimental myocardial
infarction. Circulation. 2002;106:3126–3132.
18. Ren G, Michael LH, Entman ML, Frangogiannis NG. Morphological
characteristics of the microvasculature in healing myocardial infarcts.
J Histochem Cytochem. 2002;50:71–79.
19. Shelton JM, Lee MH, Richardson JA, Patel SB. Microsomal triglyceride
transfer protein expression during mouse development. J Lipid Res.
2000;41:532–537.
20. McFadden DG, Charite J, Richardson JA, Srivastava D, Firulli AB, Olson
EN. A GATA-dependent right ventricular enhancer controls dHAND
transcription in the developing heart. Development. 2000;127:5331–5341.
21. Zhang CL, McKinsey TA, Olson EN. The transcriptional corepressor
MITR is a signal-responsive inhibitor of myogenesis. Proc Natl Acad Sci
U S A. 2001;98:7354–7359.
22. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J,
Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for
cardiac hypertrophy. Cell. 1998;93:215–228.
23. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and
sufficiency in estrogen receptor-regulated transcription. Cell. 2000;103:
843–852.
24. Margueron R, Duong V, Bonnet S, Escande A, Vignon F, Balaguer P,
Cavailles V. Histone deacetylase inhibition and estrogen receptor alpha
levels modulate the transcriptional activity of partial antiestrogens. J Mol
Endocrinol. 2004;32:583–594.
25. Liu XF, Bagchi MK. Recruitment of distinct chromatin-modifying com-
plexes by tamoxifen-complexed estrogen receptor at natural target gene
promoters in vivo. J Biol Chem. 2004;279:15050–15058.
26. Kurtev V, Margueron R, Kroboth K, Ogris E, Cavailles V, Seiser C.
Transcriptional regulation by the repressor of estrogen receptor activity
via recruitment of histone deacetylases. J Biol Chem. 2004;279:
24834–24843.
27. Kawai H, Li H, Avraham S, Jiang S, Avraham HK. Overexpression of
histone deacetylase HDAC1 modulates breast cancer progression by
negative regulation of estrogen receptor alpha. Int J Cancer. 2003;107:
353–358.
28. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, Cooper
M, Laznik D, Chinsomboon J, Rangwala SM, Baek KH, Rosenzweig A,
Spiegelman BM. HIF-independent regulation of VEGF and angiogenesis
by the transcriptional coactivator PGC-1alpha. Nature. 2008;451:
1008–1012.
29. Lamping KG, Christensen LP, Tomanek RJ. Estrogen therapy induces
collateral and microvascular remodeling. Am J Physiol Heart Circ
Physiol. 2003;285:H2039–H2044.
30. Battegay E. Angiogenesis–mechanisms and therapeutic approaches.
Schweiz Rundsch Med Prax. 1995;84:118–121.
31. Lee SH, Wolf PL, Escudero R, Deutsch R, Jamieson SW, Thistlethwaite
PA. Early expression of angiogenesis factors in acute myocardial ische-
mia and infarction. N Engl J Med. 2000;342:626–633.
32. Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P,
Goelman G, Keshet E. Conditional switching of VEGF provides new
insights into adult neovascularization and pro-angiogenic therapy. EMBO
J. 2002;21:1939–1947.
33. Herve MA, Meduri G, Petit FG, Domet TS, Lazennec G, Mourah S,
Perrot-Applanat M. Regulation of the vascular endothelial growth factor
(VEGF) receptor Flk-1/KDR by estradiol through VEGF in uterus. J
Endocrinol. 2006;188:91–99.
34. Toyota E, Matsunaga T, Chilian WM. Myocardial angiogenesis. Mol Cell
Biochem. 2004;264:35–44.
35. Wurzel J, Goldman BI. Angiogenesis factors in acute myocardial ische-
mia and infarction. N Engl J Med. 2000;343:148–149.
36. Lu J, McKinsey TA, Nicol RL, Olson EN. Signal-dependent activation of
the MEF2 transcription factor by dissociation from histone deacetylases.
Proc Natl Acad Sci U S A. 2000;97:4070–4075.
37. Lu J, McKinsey TA, Zhang CL, Olson EN. Regulation of skeletal myo-
genesis by association of the MEF2 transcription factor with class II
histone deacetylases. Mol Cell. 2000;6:233–244.
38. Gossett LA, Kelvin DJ, Sternberg EA, Olson EN. A new myocyte-
specific enhancer-binding factor that recognizes a conserved element
associated with multiple muscle-specific genes. Mol Cell Biol. 1989;9:
5022–5033.
39. Leong H, Sloan JR, Nash PD, Greene GL. Recruitment of histone
deacetylase 4 to the N-terminal region of estrogen receptor alpha. Mol
Endocrinol. 2005;19:2930–2942.
40. Song RX, Zhang Z, Santen RJ. Estrogen rapid action via protein complex
formation involving ERalpha and Src. Trends Endocrinol Metab. 2005;
16:347–353.
164 Circulation Research January 8, 2010
 at Vrije on July 11, 2011http://circres.ahajournals.org/Downloaded from 
41. Backs J, Olson EN. Control of cardiac growth by histone acetylation/
deacetylation. Circ Res. 2006;98:15–24.
42. Mahmoodzadeh S, Eder S, Nordmeyer J, Ehler E, Huber O, Martus P,
Weiske J, Pregla R, Hetzer R, Regitz-Zagrosek V. Estrogen receptor
alpha up-regulation and redistribution in human heart failure. FASEB J.
2006;20:926–934.
43. Nordmeyer J, Eder S, Mahmoodzadeh S, Martus P, Fielitz J, Bass J,
Bethke N, Zurbrugg HR, Pregla R, Hetzer R, Regitz-Zagrosek V.
Upregulation of myocardial estrogen receptors in human aortic steno-
sis. Circulation. 2004;110:3270 –3275.
44. Kao HY, Downes M, Ordentlich P, Evans RM. Isolation of a novel
histone deacetylase reveals that class I and class II deacetylases promote
SMRT-mediated repression. Genes Dev. 2000;14:55–66.
45. Huang EY, Zhang J, Miska EA, Guenther MG, Kouzarides T, Lazar MA.
Nuclear receptor corepressors partner with class II histone deacetylases in
a Sin3-independent repression pathway. Genes Dev. 2000;14:45–54.
46. Kim MY, Woo EM, Chong YT, Homenko DR, Kraus WL. Acetylation
of estrogen receptor alpha by p300 at lysines 266 and 268 enhances the
DNA binding and transactivation activities of the receptor. Mol Endo-
crinol. 2006;20:1479 –1493.
47. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid
MC, Kleinman HK, Schnaper HW. Estrogen promotes angiogenic
activity in human umbilical vein endothelial cells in vitro and in a murine
model. Circulation. 1995;91:755–763.
48. Shifren JL, Tseng JF, Zaloudek CJ, Ryan IP, Meng YG, Ferrara N, Jaffe
RB, Taylor RN. Ovarian steroid regulation of vascular endothelial growth
factor in the human endometrium: implications for angiogenesis during
the menstrual cycle and in the pathogenesis of endometriosis. J Clin
Endocrinol Metab. 1996;81:3112–3118.
49. Greb RR, Heikinheimo O, Williams RF, Hodgen GD, Goodman AL.
Vascular endothelial growth factor in primate endometrium is regulated
by oestrogen-receptor and progesterone-receptor ligands in vivo. Hum
Reprod. 1997;12:1280–1292.
50. Krasinski K, Spyridopoulos I, Asahara T, van der Zee R, Isner JM,
Losordo DW. Estradiol accelerates functional endothelial recovery after
arterial injury. Circulation. 1997;95:1768–1772.
51. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr
Opin Biotechnol. 2000;11:617–624.
52. Hyder SM, Stancel GM, Chiappetta C, Murthy L, Boettger-Tong HL,
Makela S. Uterine expression of vascular endothelial growth factor is
increased by estradiol and tamoxifen. Cancer Res. 1996;56:3954–3960.
53. Kazi AA, Jones JM, Koos RD. Chromatin immunoprecipitation analysis
of gene expression in the rat uterus in vivo: estrogen-induced recruitment
of both estrogen receptor alpha and hypoxia-inducible factor 1 to the
vascular endothelial growth factor promoter. Mol Endocrinol. 2005;19:
2006–2019.
54. Hamilton KL, Gupta S, Knowlton AA. Estrogen and regulation of heat
shock protein expression in female cardiomyocytes: cross-talk with NF
kappa B signaling. J Mol Cell Cardiol. 2004;36:577–584.
55. Murphy E, Steenbergen C. Gender-based differences in mechanisms of
protection in myocardial ischemia-reperfusion injury. Cardiovasc Res.
2007;75:478–486.
56. van Eickels M, Grohe C, Cleutjens JP, Janssen BJ, Wellens HJ,
Doevendans PA. 17beta-estradiol attenuates the development of pressure-
overload hypertrophy. Circulation. 2001;104:1419–1423.
57. Kang YK, Guermah M, Yuan CX, Roeder RG. The TRAP/mediator
coactivator complex interacts directly with estrogen receptors alpha and
beta through the TRAP220 subunit and directly enhances estrogen
receptor function in vitro. Proc Natl Acad Sci U S A. 2002;99:2642–2647.
58. Kong Y, Tannous P, Lu G, Berenji K, Rothermel BA, Olson EN, Hill JA.
Suppression of class I and II histone deacetylases blunts pressure-
overload cardiac hypertrophy. Circulation. 2006;113:2579–2588.
59. Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and
development as anticancer agents. Expert Opin Investig Drugs. 2005;14:
1497–1511.
60. Mai A, Massa S, Pezzi R, Simeoni S, Rotili D, Nebbioso A, Scognamiglio
A, Altucci L, Loidl P, Brosch G. Class II (IIa)-selective histone
deacetylase inhibitors. 1. Synthesis and biological evaluation of novel
(aryloxopropenyl)pyrrolyl hydroxyamides. J Med Chem. 2005;48:
3344–3353.
van Rooij et al Class II HDACs and ER-Mediated Cardioprotection 165
 at Vrije on July 11, 2011http://circres.ahajournals.org/Downloaded from 
1 
 
Supplemental Material 
 
Surgical procedures. All animal protocols were approved by the Institutional Animal Care and Use 
Committee of the University of Texas Southwestern Medical Center. Adult age matched HDAC9 
knockout (KO), HDAC5 KO mice and wild type (WT) mice of either sex received a MI. Adult age 
matched HDAC9 knockout (KO), HDAC5 KO mice and wild type (WT) mice of either sex were 
anesthetized with 2.4% isoflurane and placed in a supine position on a heating pad (37°C). Animals were 
intubated with a 19G stump needle and ventilated with room air using a MiniVent mouse ventilator 
(Hugo Sachs Elektronik, Germany; stroke volume 250 µl, respiratory rate 210 breaths per minute). Via 
left thoracotomy between the fourth and fifth ribs, the left anterior coronary artery (LCA) was visualized 
under a microscope and ligated using a 6-0 prolene suture. Regional ischemia was confirmed by visual 
inspection under a dissecting microscope (Leica) by discoloration of the occluded distal myocardium. 
Sham operated animals underwent the same procedure without occlusion of the LCA.  
At 4 weeks of age, mice were either sham operated or ovariectomized (ovex), and either left untreated or 
treated with 17ß estradiol (0.16 µg/d) for 4 weeks. Anesthesia was induced by intraperitoneal injection of 
100 mg/kg ketamine and 10 mg/kg xylazine, after which the lumbar dorsum is shaved bilaterally and the 
exposed skin prepared for aseptic surgery (a 10% povidone-iodine scrub followed by a 70% alcohol 
wipe). For each ovary, a 3/4 cm dorsal flank incision penetrating the abdominal cavity was made. The 
exposed ovary and associated oviduct were severed and removed, after which the incision was closed by a 
suture. The animals were treated with saline or 17ß estradiol (0.16 µg/d) for 4 weeks . 
Transthoracic echocardiography. Three weeks following MI, two-dimensional echocardiography was 
performed in conscious mice using the fully digital Vingmed System (GE Vingmed Ultrasound, Horten, 
Norway) and a 11.5-MHz linear array transducer as previously described.  Briefly, cine loops and still 
images were digitally stored for subsequent analysis using the EchoPac software (GE Vingmed 
Ultrasound). Two-dimensional short-axis views of the LV at the level of the tip of the papillary muscle 
were recorded with a typical frame rate of 263/s. Left ventricular (LV) parameters and heart rates were 
obtained from M-mode interrogation in a short-axis view. M-mode tracings were used to measure 
posterior wall thicknesses at end-diastole and end-systole (PWthd, PWths, respectively), and LV internal 
diameter (LVID) was measured as the largest anteroposterior diameter in either diastole (LVIDd) or 
systole (LVIDs). The data were analyzed by a single observer blinded to the murine genotype. LV 
fractional shortening (FS) was calculated according to the following formula: FS (%) = [(LVIDd -
LVIDs)/LVIDd] x100. All echocardiographical analyses were performed in a blinded fashion for 
genotype. 
 
Histology and histochemistry. After collecting, heart tissue was either cryo-embedded, or incubated for 
30 minutes in Krebs buffer (118mM NaCl, 4.7mM KCL, 1.2mM KH2PO4, 1.2 MgSO4, 25mM NaHCO3, 
11mM glucose) to arrest the heart in diastole, fixed in 3.7% paraformaldehyde, and embedded in paraffin. 
Sections were stained with hematoxylin and eosin to visualize infarcted area (n = 3-6 in each group). To 
examine the capillary density, all sections were incubated with biotinylated Griffiona simplicifolia lectin 
(Vector Laboratories, UK). Briefly, sections were pretreated with 3% hydrogen peroxide to inhibit 
endogenous peroxidase activity and incubated with 2% horse serum. Subsequently, they were incubated 
with biotinylated Griffonia (Bandeiraea) simplicifolia lectin I (Vector) (20 µg/ml with 10 mM HEPES, 
pH 7.5, 0.15 M NaCl) for 30 min at room temperature. After rinsing with PBS, the slides were incubated 
for 30 min with ABC reagent. Subsequently all sections were stained for immunoperoxidase using a 
commercially available kit (HRP DakoCytomation, Denmark). Final color products were developed using 
a solution containing 3,3'-diaminobenzidine (DAB) and the sections were counterstained with eosin. 
Serial transverse sections were cut at 10 µm using a Frigocut 2800 cryostat (Leica, Milton Keynes, U.K.). 
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RNA extraction and RT-PCR analysis. Total RNA from the infarcted area was isolated using Trizol 
(Invitrogen). A 10 µg aliquot representative of three animals per sample group was then analyzed on 
Affymetrix U74Av2 microarrays. A subset of differentially expressed RNAs was further characterized by 
either semi-quantitative PCR or quantitative real time PCR. Briefly, 2 µg RNA from each sample was 
used to generate cDNA using Super Script II reverse transcriptase per manufacturer’s specifications 
(Invitrogen Life Technologies Inc., Burlington, Ontario, Canada). Real time PCR was cycled between 95 
°C/30 s and 60 °C/30 for 40 cycles, following an initial denaturation step at 95°C for 3 min. 
Amplification products were routinely checked using dissociation curve software (Biorad), and transcript 
quantities were compared using the relative Ct method, where the amount of target normalised to the 
amount of endogenous control (18S) and relative to the control sample is given by 2– Ct. Real time PCR 
results were verified by electrophoresis of the reverse transcribed material in 1.2% agarose gels and 
visualized under UV illumination after ethidium bromide staining.  
 
In situ hybridization. Section in situ hybridization was performed on fresh-frozen tissue four days after 
either sham surgery or myocardial infarction. For pre-hybridization, slides were heated to 58°C for 30 
min. Utilizing RN'ase-free glass staining dishes and metal racks (Shandon, Pittsburgh, PA), slides were 
deparaffinized in xylene and hydrated through a series of graded ethanol/DEPC-saline rinses (95%, 85%, 
60%, 30%) to DEPC-saline. To accomplish microwave RNA retrieval, the slides were transferred to 
upright plastic racks and immersed in plastic containers (Miles Tissue-Tek, Elkhart, IN) filled with DEPC-
1X Antigen Retrieval Citra pH 6.0 (Biogenex, San Ramon, CA). Empty slots were filled with blank slides, 
and the plastic slide dish was covered loosely. The slides were heated in a 750 watt microwave at 90% 
power for 5 min. Any evaporated solution was replaced with DEPC-H2O, and the container was heated at 
60% power for an additional 5 min. The slides were cooled for 20 min, then returned to their metal racks 
and washed twice in DEPC-PBS, pH 7.4, for 5 min each. Subsequently, the slides were fixed for 20 min 
in 4% paraformaldehyde/DEPC-PBS, pH 7.4, and washed twice in DEPC-PBS, pH 7.4, for 5 min each. 
To further unmask RNA, the slides were permeabilized for 7.5 min with 20 µg/ml pronase-E in 50 mM 
Tris-HCl, pH 8.0/5 mM EDTA, pH 8.0/DEPC-H2O. Excess pronase-E was removed by a 5-min DEPC-
PBS, pH 7.4, wash before re-fixing in 4% paraformaldehyde/ DEPC-PBS, pH 7.4, for 5 min. Slides were 
washed in DEPC-PBS, pH 7.4, for 3 min. The slides were then acetylated in 0.25% acetic anhydride/0.1 
M triethanolamine;–HCl, pH 7.5, twice for 5-min. Next, the slides were equilibrated in 1 x SSC, pH 7.0, 
for 5 min followed by incubation in 50 mM n-ethylmaleimide/1 x SSC, pH 7.0, for 20 min. Five-min 
washes in DEPC-PBS, pH 7.4, and DEPC-saline followed and then the slides were dehydrated through 
graded ethanol/DEPC-saline rinses (30%, 60%, 85%, 95%) to absolute ethanol, and dried under vacuum 
for 2 h.  
 
The coding regions of VEGFa, and VEGFr2 were subcloned into pCDNA, linearized and transcribed as 
follows: antisense VEGFa, BamHI and T3; antisense Flk-1, NotI and T7, generously provided by Dr. T. 
Sato, at UT Southwestern. Riboprobes and hybridization mixture containing 50% formamide, 0.3 M 
NaCl, 20 mM Tris-HCl, pH 8.0, 5 mM EDTA, pH 8.0, 10 mM NaPO4, pH 8.0, 10% dextran sulfate, 1 x 
Denhardt's, and 0.5 mg/ml tRNA were thawed from -80°C storage. Probes were diluted in aliquots of 
hybridization mixture sufficient to achieve 7.5 x 103 cpm/µl and the mixture heated to 95°C for 5 min. 
Diluted probes were then cooled to 37°C and 1 M DTT was added to achieve a final concentration of 10 
mM DTT. Riboprobe was applied directly over the section, and slides were placed in a Nalgene utility box 
lined with 5 x SSC/50% formamide-saturated gel blot paper. Each slide was coverslipped with parafilm.  
 
The box was sealed and slides were hybridized for 14 h at 55°C.  
After hybridization, parafilm coverslips were removed and the slides were placed in upright plastic racks 
and immersed in a 5 x SSC/10 mM DTT wash at 55°C for 40 min. Subsequently, the slides were washed 
for 30 min at 65°C in HS (2 x SSC/50% formamide/100 mM DTT), followed by three 10-min washes in 
NTE (0.5 M NaCl/10 mM Tris-HCl, pH 8.0/5 mM EDTA, pH 8.0) at 37°C. Slides were transferred to a 
fourth NTE wash containing RN'ase-A (2 µg/ml) and incubated 30 min at 37°C. Excess RN'ase-A was 
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removed in a fifth NTE wash for 15 min at 37°C, before the slides were returned to HS for another 30 min 
at 65°C. After this second HS, the slides were washed for 15 min at 37°C each in 2 x SSC and 0.1 x SSC. 
Finally, the slides were dehydrated in graded ethanol rinses (30%, 60%, 85%, 95%) to absolute ethanol, 
and dried under vacuum.  
 
Electrophoretic mobility shift assays. Oligonucleotides corresponding to the conserved MEF2-binding 
site in the ERα regulatory region, and the mutated MEF2-binding sites were synthesized (Integrated DNA 
Technology) as follows (+ strand sequences are shown with the MEF2 site in bold and the mutation 
underlined):  
 
ERα MEF2 site 1:            5' GGCTTCTCGATACTTATTTATATATATTAGATATT-3'  
ERα MEF2mut site 1:            5' GGCTTCTCGATACTTACCCGTATATATTAGATATT-3' 
ERα MEF2 site 2 oligo:        5' GGCCACTGGTGCTAAATATAGCTGTCGGTGG -3'  
ERα MEF2mut site 2 oligo:  5' GGCCACTGGTGCTAGGCGTAGCTGTCGGTGG -3' 
ERα MEF2 site 3 oligo:        5' GGCTCTTTCCAGATGTATTTATAGTAGAAG -3'  
ERα MEF2mut site 3 oligo:  5' GGCTCTTTCCAGATGTACCCGTAGTAGAAG -3' 
 
Annealed oligonucleotides were radiolabeled with [32P]dCTP using the Klenow fragment of DNA 
polymerase and purified using G50 spin columns (Roche). Nuclear cell extracts were isolated from Cos-1 
cells that were transfected with pcDNAMYC-MEF2C. Unlabeled oligonucleotides used as competitors 
were annealed as described above and added to the reactions at the indicated concentrations. DNA-protein 
complexes were resolved on 5% polyacrylamide native gels and the gels were exposed to BioMax X-ray 
film (Kodak). 
 
GST pulldown. GST-ERα was generated by subcloning PCR amplified fragment into EcoRI and XhoI 
sites of the pGEX-KG vector, while GST-dHDAC9 (aa131-586) was subcloned in the pGEX-KG vector 
as a XbaI-XhoI fragment. Plasmids encoding fusion proteins were transformed into BL21-codon plus 
cells (Stratagene). After growing up the cells and inducing protein expression, the culture was incubated 
at room temperature for 4 to 6 h, after which the cells were harvested and GST protein was purified with 
glutathione beads in accordance with the Amersham procedure. 
 
Proteins translated in vitro were labeled with [35S]methionine in a coupled transcription-translation T7 
reticulocyte lysate system (Promega). Glutathione beads conjugated with 1 ug of protein were incubated 
with 10 ul of TNT product at 4˚C for 2 h in 500 ul of GST-binding buffer (20 mM Tris [pH 7.3], 150 mM 
NaCl, 0.5% NP-40, protease inhibitor cocktail from Roche, 1 mM phenylmethylsulfonyl fluoride 
[PMSF]). The beads were washed three times with GST-binding buffer. Fifty microliters of sodium 
dodecyl sulfate (SDS) loading buffer was then added to the beads. After boiling, 20 ul was loaded onto an 
SDS-PAGE gel and analyzed by autoradiography. 
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Supplemental Figures 
 
Supplemental Figure I.  Representative M-mode images of sham or infarcted WT and HDAC9 KO 
females 3 weeks after permanent LCA ligation.  
 
Supplemental Figure II.  Representative M-mode images of sham or infarcted HDAC9 KO females that 
received ovariectomy or ovariectomy and estrogen in addition to MI, compared to WT females post-MI. 
 
Supplemental Figure III. Class II HDAC mutant male animals develop age dependent hypertrophy, 
while this remodeling is absent in female mutant mice. 
A. Histological data indicate that male mutant HDAC5 and HDAC9 mice develop age dependent cardiac 
hypertrophy while this remodeling is absent in the female mutant littermates (Scale bars: 40 μm). 
B. Heart weight versus tibia length ratio (HW /TL) indicates an age-dependent increase in class II 
HDAC mutant males while this increase is absent in females. * p<0.05 compared to male mice of the 
same genotype. 
C. Realtime PCR analysis indicates that there is a strong induction of stress responsive genes in male 
mutant animals, while this increase is severely blunted in female mice mutant for either HDAC5 or -
9. The data are expressed as fold expression compared to WT males. 
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Supplemental Table I. Primer sequences for RT-PCR analysis of angiogenic genes  
 
 
 
 
 
 
 
Supplemental Table II. Primer sequences for electrophoric mobility shift assay for MEF2 sites upstream 
of the ERα gene (+ strand sequences are shown with the MEF2 site in bold and the mutation underlined). 
 
 
MEF2 site Primer sequence 
ERα MEF2 site 1 5' GGCTTCTCGATACTTATTTATATATATTAGATATT-3'  
ERα MEF2mut site 1 5' GGCTTCTCGATACTTACCCGTATATATTAGATATT-3' 
ERα MEF2 site 2  5' GGCCACTGGTGCTAAATATAGCTGTCGGTGG-3'  
ERα MEF2mut site 2 5' GGCCACTGGTGCTAGGCGTAGCTGTCGGTGG -3' 
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Supplemental Table III. Echocardiographic analysis of either HDAC5 KO females and HDAC9 KO 
females versus WT females indicates less dilation and a better maintenance of fractional shortening in 
class II HDAC mutant females in response to MI. * p<0.05 compared to corresponding WT females. 
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Supplemental Table IV. Morphometric analysis of either WT or HDAC9 KO females 3 weeks post-MI 
indicates signs of hypertrophy and failure in the WT females, which are severely blunted in the HDAC9 
KO females. * p<0.05 compared to corresponding WT female. 
 
 
 
 
 
* 
* 
* 
* 
* 
* 
* 
* 
* 
 at Vrije on July 11, 2011http://circres.ahajournals.org/Downloaded from 
 8 
Supplemental Table V. Gene expression analysis by microarray on the infarcted region HDAC9 KO 
females versus WT females indicates upregulation of ER signaling related genes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ER coactivators/ repressors  Fold upregulation 
 
-PBP     69 x  
-Ah receptor repressor   19.7 x 
-pCAF     16 x 
-Interferon activated gene  14.9 x 
-PKC     8.0 x 
-Rho GTPase    3.2 x 
    
-ER targets 
-GABA-A receptor   10.6 x 
-17-β hydroxysteroid   9.8 x 
-ATP binding cassette   8.0 x 
-Progesteron receptor   5.6 x 
-Muscle creatine kinase  4.0 x 
 
Angiogenic factors 
-angiopoetin    19.7 x 
-FGF related gene   3.0 x 
-VEGF-B precursor   3.0 x 
-VEGF-A    1.7 x 
 
-ERRβ     2.3 x 
-ERRα     2.0 x 
-ERα     1.6 x 
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Supplemental Table VI. Echocardiographic analysis of HDAC9 KO females after ovariectomy and 
subsequent supplementation of estrogen indicates a decrease in fractional shortening in ovariectomized 
HDAC9 mutant females post-MI while the protective effect is restored by estrogen treatment. * p<0.05 
compared to HDAC9 mutant females post-MI. 
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Supplemental Figure 1.  Representative M-mode images of sham or infarcted WT and HDAC9 KO females 3 weeks after 
permanent LCA ligation. 
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Supplemental Figure 2.  Representative M-mode images of sham or infarcted HDAC9 KO females that received ovariec-
tomy or ovariectomy and estrogen in addition to MI, compared to WT females post-MI.
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Supplemental Figure 3. Class II HDAC mutant male animals develop age dependent hypertrophy, while this 
remodeling is absent in female mutant mice.
A. Histological data for 5-6 month old animals indicate that male mutant HDAC5 and HDAC9 mice develop age  
 dependent cardiac hypertrophy while this remodeling is absent in the female mutant littermates 
 (Scale bars: 40 µm).
B. Heart weight versus tibia length ratio (HW /TL) indicates an age-dependent increase in class II HDAC mutant   
 males while this increase is absent in females. * p<0.05 compared to male mice of the same genotype.
C. Realtime PCR analysis indicates that there is a strong induction of stress responsive genes in male mutant   
 animals, while this increase is severely blunted in female mice mutant for either HDAC5 or -9. The data are   
 expressed as fold expression compared to WT males.
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